Prognostic Factors In Ovarian Cancer.
M. Friedlander, A. Dembo
Published 1991 · Medicine
Download PDFAnalyze on Scholarcy
Epithelial ovarian cancers vary considerably in their biologic behavior and this is reflected in the variety of clinicopathologic factors that are used for predicting outcome. This article assesses the potential value of some of the newer prognostic factors and critically evaluates the more commonly used clinicopathologic variables.
This paper is referenced by
Variation in NFk B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer
M. Block (2014)
The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer
Y. Liu (2017)
5T4 oncofetal antigen expression in ovarian carcinoma
E. Wrigley (1994)
Failure of BRCA1 dysfunction to alter ovarian cancer survival.
R. Buller (2002)
Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
V. Ouellet (2008)
Investigating the potential for expediting diagnosis of ovarian cancer via prompt symptom recognition & "targeted screening"
A. W. Lim (2009)
The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer
H. de Lassus (2007)
Vascular Endothelial Growth Factor Expression in Ovarian Cancer : AModel forTargeted Use of NovelTherapies ?
T. Duncan (2008)
Biomarker conservation in primary and metastatic epithelial ovarian cancer.
K. Tewari (2000)
Inhibition of Angiogenesis Associated with Ovarian Cancer By Nanoparticles of Cerium Oxide (CIP)
Sudipta Seal (2016)
Public perception of risk-reducing salpingectomy for preventing ovarian cancer
Jun Hyeok Kang (2015)
Expression and Prognostic Significance of Cyclin D3 in Ovarian Adenocarcinomas
G. Levidou (2007)
Current Drug Treatment Guidelines for Epithelial Ovarian Cancer
P. Lorigan (2012)
BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers
Y-K Lee (2009)
Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies?
T. Duncan (2008)
Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer
G. Siddiqui (2010)
Nanozymology: Connecting Biology and Nanotechnology
D. J. Lockwood (2020)
Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling
V. Ouellet (2005)
SET complex in serous epithelial ovarian cancer.
V. Ouellet (2006)
Prognostic evaluation of preoperative serum C-reactive protein concentration in patients with epithelial ovarian cancer.
Yaping Lu (2015)
MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer
Sha Xiao (2018)
Clonal chromosome abnormalities in 54 cases of ovarian carcinoma.
F. Thompson (1994)
METHODS OF PROMOTING ANGIOGENESIS USING CERIUM OXIDE NANOPARTICLES
OXIDE NANOPARTICLES (2020)
Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
V. Ouellet (2006)
Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
J. Paek (2011)
Prognostic Significance of Cell-Matrix Interactions in Epithelial Ovarian Cancer
S. Sillanpää (2007)
Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma
N. Nishida (2004)
Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer.
Joanna Narkiewicz (2008)
Comparison of clinical staging of benign and malignant ovarian tissues with DNA flow cytometry
Jerry T. Thornthwaite (2013)
Conventional and Proteomic Technologies for the Detection of Early Stage Malignancies: Markers for Ovarian Cancer
C. Lee (2007)
Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer
C. Maine (2013)
Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-Associated Trypsin Inhibitor in Ovarian Cancer
A. Paju (2004)See more